Regencell’s 23% Rally: How Traditional Medicine Drives Neuro‑Cognitive Growth and Investor Optimism
Regencell’s 23% rally shows investors confidence in its traditional‑medicine neuro‑cognitive pipeline. With a $7.91 bn market cap and aggressive R&D, it offers high‑risk, high‑potential upside for long‑term biotech investors.
- Regencell Bioscience Holdings Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read